Analysis of Driver Mutations in Female Non-Smoker Asian Patients with Pulmonary Adenocarcinoma

Cell Biochemistry and Biophysics

Volumn 64, Issue 2, 2012, Pages 155-160

  Ren, Shengxiang ^a   Kuang, Peng ^a   Zheng, Limou ^b   Su, Chunxia ^a   Li, Jiayu ^a   Li, Bing ^a   Chen, Xiaoxia ^a   Wang, Yongshen ^a   KimCurran, V ^a   Liu, Lu ^a   Hu, Qiong ^a   Zhang, Jie ^a   Tang, Liang ^a   Zhou, Caicun ^a  

^a TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

^b XIAMEN UNIVERSITY   (China)

Author keywords

Asian; Female; Mutation driver; Non smoker; Pulmonary adenocarcinoma

Indexed keywords

B RAF KINASE; BRAF PROTEIN, HUMAN; EGFR PROTEIN, HUMAN; EML4 ALK FUSION PROTEIN, HUMAN; EML4-ALK FUSION PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; KRAS PROTEIN, HUMAN; ONCOPROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; RAS PROTEIN;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; ASIAN; CANCER STAGING; EXON; FEMALE; GENETICS; HUMAN; LUNG TUMOR; MIDDLE AGED; MUTATION; NUCLEOTIDE SEQUENCE; SMOKING;

ADENOCARCINOMA; ADULT; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; DNA MUTATIONAL ANALYSIS; EXONS; FEMALE; HUMANS; LUNG NEOPLASMS; MIDDLE AGED; MUTATION; NEOPLASM STAGING; ONCOGENE PROTEINS, FUSION; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SMOKING;

EID: 84867743860     PISSN: 10859195     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12013-012-9384-8     Document Type: Article

References (28)

1. Siegel, R., Ward, E., Brawley, O., & Jemal, A. (2011). Cancer statistics, 2011: The impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA: A Cancer Journal for Clinicians, 61, 212-236.
2. Samet, J. M. (2004). Adverse effects of smoke exposure on the upper airway. Tobacco Control, 13(Suppl 1), i57-i60.
3. Samet, J. M., Avila-Tang, E., Boffetta, P., Hannan, L. M., Olivo-Marston, S., et al. (2009). Lung cancer in never smokers: Clinical epidemiology and environmental risk factors. Clinical Cancer Research, 15, 5626-5645.
4. Thatcher, N., Chang, A., Parikh, P., Rodrigues Pereira, J., Ciuleanu, T., et al. (2005). Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: Results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet, 366, 1527-1537.
5. Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., et al. (2004). Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. New England Journal of Medicine, 350, 2129-2139.
6. Mok, T. S., Wu, Y. L., Thongprasert, S., Yang, C. H., Chu, D. T., et al. (2009). Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. New England Journal of Medicine, 361, 947-957.
7. Maemondo, M., Inoue, A., Kobayashi, K., Sugawara, S., Oizumi, S., et al. (2010). Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. New England Journal of Medicine, 362, 2380-2388.
8. Rosell, R., Gervais, R., & Vergnenegre, A. (2011). Spanish Lung Cancer Group. Erlotinib versus chemotherapy (CT) in advanced non-small cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations: Interim results of the European erlotinib versus chemotherapy (EURTAC) phase III randomized trial. Journal Clinical Oncology, 29, 7503.
9. Zhou, C. C., Wu, Y. L., Chen, G. Y., Feng, J. F., Liu, X. Q., et al. (2011). Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): A multicentre, open-label, randomised, phase 3 study. Lancet Oncology, 12, 735-742.
10. Ettinger, D. S., Akerley, W., Bepler, G., Blum, M. G., Chang, A., et al. (2010). Non-small cell lung cancer. Journal of National Comprehensive Cancer Network, 8, 740-801.
11. Shaw, A. T., Yeap, B. Y., Mino-Kenudson, M., Digumarthy, S. R., Costa, D. B., et al. (2009). Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. Journal Clinical Oncology, 27, 4247-4253.
12. Bang, Y., & Al, E. (2010). Clinical activity of the oral ALK inhibitor PF-02341066 in ALK-positive patients with non-small cell lung cancer (NSCLC). Journal of Clinical Oncology, 28.
13. Gadgeel, S. M., & Bepler, G. (2011). Crizotinib: An anaplastic lymphoma kinase inhibitor. Future Oncology, 7, 947-953.
14. Weir, B. A., Woo, M. S., Getz, G., Perner, S., Ding, L., et al. (2007). Characterizing the cancer genome in lung adenocarcinoma. Nature, 450, 893-898.
15. Zhou, C. C., Ren, S. X., Zhou, S. W., Zhang, L., Xu, J. F., et al. (2010). High-level mRNA of excision repair cross-complementation group 1 gene is associated with poor outcome of platinum-based doublet chemotherapy of advanced nonsmall cell lung cancer patients. Cancer Investigation, 28, 1078-1083.
16. Wilson, R. K., Ding, L., Getz, G., Wheeler, D. A., Mardis, E. R., et al. (2008). Somatic mutations affect key pathways in lung adenocarcinoma. Nature, 455, 1069-1075.
17. Rikova, K., Guo, A., Zeng, Q., Possemato, A., Yu, J., et al. (2007). Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell, 131, 1190-1203.
18. Simon, R., & Youn, A. (2011). Identifying cancer driver genes in tumor genome sequencing studies. Bioinformatics, 27, 175-181.
19. Carvajal, R. D., Antonescu, C. R., Wolchok, J. D., Chapman, P. B., Roman, R. A., et al. (2011). KIT as a therapeutic target in metastatic melanoma. JAMA, the Journal of the American Medical Association, 305, 2327.
20. Cantley, L. C., Engelman, J. A., Chen, L., Tan, X. H., Crosby, K., et al. (2008). Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nature Medicine, 14, 1351-1356.
21. Pao, W., & Girard, N. (2011). New driver mutations in non-small-cell lung cancer. Lancet Oncology, 12, 175-180.
22. Pao, W., Balak, M., Riely, G., Li, A., Zakowski, M., et al. (2006). Molecular analysis of NSCLC patients with acquired resistance to gefitinib or erlotinib. Journal of Clinical Oncology, 24, 7078.
23. Pao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., et al. (2005). Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Medicine, 2, e73.
24. Fukuoka, M., Wu, Y. L., Thongprasert, S., Sunpaweravong, P., & Leong, S. S., et al. (2011). Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small cell lung cancer in Asia (IPASS). Journal of Clinical Oncology.
25. Zhou, Q., Zhang, X. C., Chen, Z. H., Yin, X. L., Yang, J. J., et al. (2011). Relative abundance of EGFR mutations predicts benefit from gefitinib treatment for advanced non-small-cell lung cancer. Journal of Clinical Oncology, 29, 3316-3321.
26. Huang, S. F., Wu, C. C., Hsu, H. Y., Liu, H. P., Chang, J. W. C., et al. (2008). Reversed mutation rates of KRAS and EGFR genes in adenocarcinoma of the lung in Taiwan and their implications. Cancer, 113, 3199-3208.
27. Chen, H. Q., Sun, Y. H., Ren, Y., Fang, Z. Y., Li, C. G., et al. (2010). Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases. Journal of Clinical Oncology, 28, 4616-4620.
28. Kris, M., Johnson, B., & Kwiatkowski, D. (2011). Identification of driver mutations in tumor specimens from 1, 000 patients with lung adenocarcinoma: The NCI's lung cancer mutation consortium (LCMC).